Drugs organized from botulinum toxin are injected in microscopic quantities in distinct muscles that call for treatment. The drug binds into the nerve terminals and blocks the release of acetylcholine, relaxing the targeted muscles. On August two, 2010, the US FDA introduced the acceptance of incobotulinumtoxinA (Xeomin®) to the https://jetonlinepharma.us/product-category/botulinum-toxins/